Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications
Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs) that has Level A evidence, the effectiveness of which has been proven in three controlled clinical trials: ASSIST, ASTIS, and SCOT. Despite th...
Main Authors: | O. B. Ovsyannikova, L. P. Ananyeva, O. A. Koneva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoitova, A. M. Lila |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-02-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1102 |
Similar Items
-
Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 1. Clinical aspects
by: O. B. Ovsyannikova, et al.
Published: (2020-11-01) -
Monitoring of chimerism after allogeneic hematopoietic stem cell transplantation
by: D. S. Dubnyak, et al.
Published: (2022-12-01) -
Immunological features in anti-U1-ribonucleoprotein antibody positive patients with systemic scleroderma
by: R. U. Shayakhmetova, et al.
Published: (2020-03-01) -
Use of the international systemic scleroderma activity index
by: Maya Nikolayevna Starovoitova, et al.
Published: (2013-03-01) -
COMPLEX THERAPY FOR VASCULAR DISORDERS IN PATIENTS WITH SCLERODERMA SYSTEMATICA
by: M N Starovoitova, et al.
Published: (2009-06-01)